{
}
The global cancer immunotherapy market is projected to reach $135.2 billion in 2024, growing at a CAGR of 9.8% to $236.9 billion by 2030, driven by rising cancer prevalence and demand for effective treatments. North America leads the market, while Asia-Pacific is the fastest-growing region. Monoclonal antibodies dominate the product segment, with lung cancer applications holding the largest market share, and breast cancer expected to grow the fastest.
The Congestive Heart Failure market is poised for significant growth, driven by an increase in prevalence and the introduction of innovative therapies like finerenone, tirzepatide, and semaglutide. Key players such as Novartis, Eli Lilly, and Bayer are advancing their drug candidates through clinical development, while off-label therapies and generics continue to dominate the current market landscape. The FDA's recent approvals and label expansions are expected to further enhance treatment options and accessibility for patients.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, Morrison brings extensive experience in clinical development, having overseen the approval of several notable drugs. He expressed enthusiasm for joining the innovative company and contributing to its mission of developing transformative gene-based medicines.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, including leadership roles at AstraZeneca and Pfizer, Morrison's expertise in clinical development is expected to enhance the company's innovative pipeline. He has overseen the development of notable drugs such as Tagrisso®, Imfinzi®, and Lynparza®.
Vertex Pharmaceuticals has partnered with Orna Therapeutics, investing $65 million to develop next-gen gene therapies for sickle cell disease and transfusion-dependent beta thalassemia. This collaboration allows Orna to expand its research capabilities and leverage its lipid nanoparticle delivery technology, aiming to create accessible treatments that bypass traditional cell therapy limitations. Vertex's recent FDA approvals for gene therapies in these areas further enhance the significance of this partnership.
The semaglutides market is projected to grow from $20.54 billion in 2023 to $36.87 billion by 2028, driven by rising diabetes prevalence and increased demand for effective treatments. Key players are innovating with GLP-1 receptor analogues and oral formulations to enhance patient adherence and reduce side effects. North America leads the market, while Asia-Pacific is expected to be the fastest-growing region.
Roche is projected to lead the pharmaceutical industry in sales by 2025, despite not having any products in the top drug rankings. Eli Lilly and Novo Nordisk are expected to rise in the rankings, with combined sales from their GLP-1 drugs surpassing $70 billion this year. Meanwhile, Pfizer is anticipated to drop from fifth to ninth place, while Merck & Co. and AbbVie are expected to secure the second and third spots, respectively.
Merck has cut the price of its diabetes drug Januvia by 42%, aiming to align list prices with net prices and responding to changes in the Medicaid rebate program. Meanwhile, Neumora's experimental depression drug failed in a Phase 3 study, causing an 83% drop in its stock. Roche is expanding its presence in the antibody-drug conjugate space through a deal with Innovent Biologics, which could yield up to $1 billion in milestone payments.
DelveInsight's report on Acute Bacterial Skin and Skin-Structure Infections (ABSSSI) forecasts significant market growth by 2034, driven by rising prevalence and awareness. Key players include Glenmark Pharma and AbbVie, with therapies like Zevtera and Dalbavancin leading the charge. The report highlights a higher incidence in men and notes nearly 870,000 hospital admissions in the U.S. due to ABSSSI in 2004.
Merck & Co. is shifting its focus from TIGIT and LAG-3 inhibitors to a subcutaneous version of Keytruda and a PD-1x/VEGF bispecific, while entering the obesity market with a preclinical GLP-1 receptor agonist from Hansoh Pharma for $112 million. Sanofi reported promising mid-stage results for its TL1A antibody duvakitug in inflammatory bowel disease, achieving significant remission rates, while Vertex Pharmaceuticals faced setbacks with its NaV1.8 inhibitor suzetrigine in chronic pain trials. Novo Nordisk completed a $16.5 billion acquisition of Catalent to address supply issues for semaglutide, despite ongoing shortages, while Novartis announced the closure of two MorphoSys sites, affecting 330 employees, following an $800 million write-down on pelabresib.
Merck & Co., Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
global cancer immunotherapy market projected to reach 236.9 billion by 2030
United States Dollar
GSK plc
Bristol-Myers Squibb Company
Bayer AG
Eli Lilly and Company
Pfizer Inc.
Merck & Co., Inc.
Novartis AG
Immunocore Holdings plc
AstraZeneca PLC
Amgen Inc.
F. Hoffmann-La Roche Ltd.
IND
FRA
ARG
CAN
ESP
USA
BRA
CHN
MEX
DEU
ITA
JPN
GBR
KOR
Show more
10:06 10.01.2025
congestive heart failure market poised for significant growth by 2034
United States Dollar
Mesoblast Ltd
Eli Lilly and Co
Boehringer Ingelheim KG
Bayer AG
Merck & Co., Inc.
Bristol-Myers Squibb Co
Intra-Cellular Therapies, Inc.
BioCardia, Inc.
Novo Nordisk A/S
scPharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc.
Cytokinetics, Incorporated
Novartis AG
Tenax Therapeutics, Inc.
AstraZeneca PLC
Amgen Inc.
Otsuka Pharmaceutical Co. Ltd.
FRA
DEU
ITA
JPN
GBR
USA
Show more
15:50 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors
United States Dollar
Pfizer Inc.
AstraZeneca PLC
CRISPR Therapeutics AG
Merck & Co., Inc.
USA
Briggs Morrison
Samarth Kulkarni
Show more
14:04 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors election
United States Dollar
Vertex Pharmaceuticals Inc
AstraZeneca PLC
Bayer AG
Pfizer Inc.
Syndax Pharmaceuticals, Inc.
Merck & Co., Inc.
CHE
Briggs Morrison
Samarth Kulkarni
Show more
14:00 07.01.2025
vertex partners with orna therapeutics to advance gene therapies for blood disorders
13:00 07.01.2025
semaglutides market projected to reach 36.87 billion by 2028
United States Dollar
Adocia SA
Sanofi SA
Eli Lilly and Company
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Dr. Reddy's Laboratories Limited
Boehringer Ingelheim International GmbH
Glaxosmithkline plc
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Novartis International AG
Bristol-Myers Squibb Company
Novo Nordisk A/S
Cipla Limited
Biocon Limited
Teva Pharmaceutical Industries Ltd
AstraZeneca PLC
Amgen Inc.
ITA
IND
FRA
IDN
CAN
ESP
BRA
USA
RUS
CHN
DEU
AUS
JPN
GBR
KOR
Show more
10:12 06.01.2025
roche set to lead global pharma sales in 2025 as rivals rise
United States Dollar
Merck & Co., Inc.
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
ABBVIE
Pfizer Inc.
Novartis AG
Sanofi
AstraZeneca PLC
Gilead Sciences, Inc.
GSK plc
Eli Lilly and Co
Johnson & Johnson
Novo Nordisk A/S
Robert F. Kennedy Jr.
Show more
19:07 03.01.2025
merck cuts diabetes drug price while neumora faces setback in depression trial
United States Dollar
Merck & Co., Inc.
Innovent Biologics, Inc.
Hoffmann-La Roche AG
CHN
USA
Wilma Lee Cooper
Elaine Chen
Allison DeAngelis
Show more
15:34 03.01.2025
emerging therapies and market dynamics for acute bacterial skin infections
Merck & Co., Inc.
Wockhardt Limited
Pfizer Inc.
Glenmark Pharmaceuticals Limited
Allergan plc
Novartis AG
JPN
FRA
GBR
ESP
USA
DEU
ITA
Gaurav Bora
Show more
19:35 23.12.2024
merck shifts focus to biotech and obesity as keytruda exclusivity looms
United States Dollar
Sanofi
Vertex Pharmaceuticals Inc
Merck & Co., Inc.
Catalent, Inc.
Novartis AG
Novo Nordisk A/S
USA
Show more
04:47 20.12.2024
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Global Trade Developments
Stock Market Updates
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Private Equity Deals
Supply Chain Management
Government Economic Policies
Cryptocurrency Trends
Retail and Consumer Goods
Fintech Startups
Workplace Trends
Central Bank Actions
Central Banks and Digital Currencies
Venture Capital Investments
CEO Changes
Finance Mergers & Acquisitions
Energy Sector Developments
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Tencent Holdings Ltd
Google Inc.
NIO Inc.
Nikkei 225
Grab2Go AS
OLA ELECTRIC MOBILITY LTD
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Tesla, Inc.
MARA Holdings, Inc.
Currencies:
United States Dollar
Euro
Indian Rupee
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
New Taiwan Dollar
Indonesian Rupiah
Saudi Riyal
Offshore Chinese Yuan
Egyptian Pound
Hong Kong Dollar
Malaysian Ringgit
Filipino Peso
West African CFA Franc
South Korean Won
Thai Baht
Mexican Peso
Croatian Kuna
Bahraini Dinar
People: